Outcomes and Therapeutic Management of Bladder Cancer

• Outros Autores: Moschini, Marco (Editor)
• Formato: Recurso Electrónico Capítulo de Livro
• Idioma: inglês
• Publicado em: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Assuntos: Medicine; bladder cancer; robotic-assisted; open; radical cystectomy; survival; propensity score; age; urothelial carcinoma; outcome; anesthesia recovery periods; cognitive impairment; gamma-cyclodextrins; neuromuscular blockade; robotic radical cystectomy; glycogen; clear-cell adenocarcinoma; urinary bladder; SEER program database; female; intracorporeal neobladder; outcomes; robotic; sex-sparing; methylation; biomarkers; FOXA1; GATA3; KRT20; molecular markers; mRNA; muscle-invasive bladder cancer; PCR; human epidermal growth factor receptor 2; indoleamine 2,3-dioxygenase; programmed death ligand-1; immunotherapy; nodal disease; pN1; neoadjuvant; adjuvant; chemotherapy; n/a
• Acesso em linha: DOAB: download the publication; DOAB: description of the publication

Resumo

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

Descrição Física

1 electronic resource (120 p.)

ISBN

books978-3-03936-935-5
9783039369348
9783039369355

Acesso

Open Access